Author:
Dada Oluwabunmi,Castillo Karina,Hogan Miranda,Chalbot Marie-Cecile G.,Kavouras Ilias G.
Abstract
AbstractThe size and chemical content of particles in electronic cigarette vapors (e-vapors) dictate their fate in the human body. Understanding how particles in e-vapors are formed and their size is critical to identifying and mitigating the adverse consequences of vaping. Thermal decomposition and reactions of the refill liquid (e-liquid) components play a key role in new particles formation. Here we report the evolution of particle number concentration in e-vapors over time for variable mixtures of refill e-liquids and operating conditions. Particle with aerodynamic diameter < 300 nm accounted for up to 17% (or 780 μg/m3) of e-vapors particles. Two events of increasing particle number concentration were observed, 2–3 s after puff completion and a second 4–5 s later. The intensity of each event varied by the abundance of propylene glycol, glycerol, and flavorings in e-liquids. Propylene glycol and glycerol were associated with the first event. Flavorings containing aromatic and aliphatic unsaturated functional groups were strongly associated with the second event and to a lesser extent with the first one. The results indicate that particles in e-vapors may be formed through the heteromolecular condensation of propylene glycol, glycerol, and flavorings, including both parent chemicals and/or their thermal decomposition products.
Funder
National Cancer Institute
PSC CUNY
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Etter, J.-F. Electronic cigarettes: A survey of users. BMC Public Health 10, 231 (2010).
2. Hawkins, K. B., Johnson, A. C., Denzel, M., Tercyak, K. P. & Mays, D. Adolescents’s awareness and perceptions of e-cigarettes: Implications for intervention and tobacco regulation. Pediatrics 140, 132 (2017).
3. Pellegrino, R. M. et al. Electronic cigarettes: An evaluation of exposure to chemicals and fine particulate matter (PM). Ann. Ig. 24, 279–288 (2012).
4. US Food and Drug Adminsitration, Lung illnesses associated with use of vaping products information for the public, FDA Actions, and Recommendations (2019).
5. US Food and Drug Adminsitration, Statement on federal and state collaboration to investigate respiratory illnesses reported after use of e-cigarette products (2019).